Compare BIO-TECHNE Corp (TECH) vs Utilities Select Sector SPDR Fund (XLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Utilities Select Sector SPDR Fund — how do they compare? BIO-TECHNE Corp trades at $72.39 (market cap $11.34B), while Utilities Select Sector SPDR Fund trades at $42.95. The key difference: BIO-TECHNE Corp pays a 0.44% dividend while Utilities Select Sector SPDR Fund pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, Utilities Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| TECH | XLU | |
|---|---|---|
Market Cap | $11.34B | — |
Sector | Health | — |
52-Week High | $72.48 | $47.73 |
52-Week Low | $43.31 | $41.86 |
Enterprise Value | $11.36B | — |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
XLU trades at $43.45, up 0.86% today, with a mixed technical picture showing bullish overall signals but bearish moving averages. The utilities ETF faces conflicting narratives around AI power demand versus regulatory headwinds, with recent news highlighting both defensive appeal and concerns about concentrated AI exposure. Support levels cluster around $42-43 while resistance sits at $44.
The ETF's outlook balances defensive utility characteristics against AI-driven growth potential. Key opportunities include inflation hedging and dividend income, while risks center on regulatory intervention and uneven AI benefits across the portfolio. Current sentiment reflects cautious optimism as investors weigh utility stability against transformative power demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Utilities Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: electric utilities; water utilities; multi-utilities; independent power and renewable electricity producers; and gas utilities. The fund is non-diversified.
Read more on XLU →
